NCT00391846
Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone
See it on ClinicalTrials.gov ↗252 people
28.6%
71.4%
72 womenmiddle line = equal numbers180 men
- Phase
- PHASE4
- Paid for by
- AstraZeneca
- Finished
- 2009-01
- Health conditions
- Heart Failure, Ventricular Dysfunction, Left
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- mean 77 Years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Planned CV hospitalisation, stroke or acute myocardial infarction (MI) last 3 months,”
Study titles and rules are shown in their original English.